This lesson addresses what happens when that chain gets longer.

CRO-managed site networks have become a dominant model in industry-sponsored research. A contract research organization recruits sites into its network, provides centralized services -- regulatory submissions, document management, training platforms, quality oversight -- and in exchange, the site gains access to study opportunities that flow through the CRO rather than directly from sponsors. For the site, this model trades autonomy for volume. For the RC, it raises a question that E6(R3) answers with surprising clarity but that operational reality complicates enormously: which regulatory responsibilities can be centralized, and which must remain at the site?

Layered on top of the network question is the decentralized trial question. Remote consent. Direct-to-patient investigational product shipment. Wearable devices collecting endpoint data from participants who never visit the clinic. These are not speculative technologies. They are protocol requirements in studies your site may be conducting right now -- or will be conducting within the year. And each one redistributes the regulatory coordinator's work in ways that the traditional site-based model did not anticipate.

This lesson examines both forces -- network centralization and trial decentralization -- through the RC's operational lens. Not the sponsor's perspective, not the CRO's business model, but the practical question: what changes about your job, and what does not change no matter how the model shifts?

This lesson addresses what happens when that chain gets longer.

CRO-managed site networks have become a dominant model in industry-sponsored research. A contract research organization recruits sites into its network, provides centralized services -- regulatory submissions, document management, training platforms, quality oversight -- and in exchange, the site gains access to study opportunities that flow through the CRO rather than directly from sponsors. For the site, this model trades autonomy for volume. For the RC, it raises a question that E6(R3) answers with surprising clarity but that operational reality complicates enormously: which regulatory responsibilities can be centralized, and which must remain at the site?

Layered on top of the network question is the decentralized trial question. Remote consent. Direct-to-patient investigational product shipment. Wearable devices collecting endpoint data from participants who never visit the clinic. These are not speculative technologies. They are protocol requirements in studies your site may be conducting right now -- or will be conducting within the year. And each one redistributes the regulatory coordinator's work in ways that the traditional site-based model did not anticipate.

This lesson examines both forces -- network centralization and trial decentralization -- through the RC's operational lens. Not the sponsor's perspective, not the CRO's business model, but the practical question: what changes about your job, and what does not change no matter how the model shifts?